EMBP Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multikinase inhibitor, indirectly inhibits EMBP by disrupting the Raf/MEK/ERK pathway. As a potent inhibitor of Raf kinases, Sorafenib impedes the activation of downstream effectors, including ERK. This disruption hampers the signaling cascade that influences EMBP expression, showcasing the compound's efficacy as an indirect inhibitor through targeted modulation of the Raf/MEK/ERK pathway. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin, a natural polyphenol, indirectly inhibits EMBP by influencing the NF-κB signaling pathway. Acting as an inhibitor of NF-κB activation, Curcumin disrupts the transcriptional regulation of genes involved in inflammation and immune response, including EMBP. This indirect inhibition highlights the compound's capability to modulate EMBP expression by interfering with a specific regulatory axis associated with inflammatory signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 mitogen-activated protein kinase (MAPK) inhibitor, indirectly influences EMBP expression by targeting the p38 MAPK pathway. Inhibition of p38 MAPK disrupts downstream signaling cascades, affecting transcription factors involved in EMBP regulation. The impact of SB203580 on the p38 MAPK pathway demonstrates its efficacy as an indirect inhibitor of EMBP, offering a specific and targeted approach to modulation through the p38 MAPK signaling axis. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-DG indirectly inhibits EMBP expression by disrupting glycolysis and cellular energetics. As a glucose analog, 2-DG competitively inhibits glucose uptake, leading to metabolic stress. This metabolic perturbation triggers AMP-activated protein kinase (AMPK) activation, influencing downstream pathways associated with EMBP regulation. The disruption of cellular energetics by 2-DG highlights its potential as an indirect inhibitor of EMBP, linking metabolism to EMBP expression dynamics. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, indirectly inhibits EMBP by disrupting the Src family kinases (SFK) signaling pathway. By inhibiting SFKs, Dasatinib interferes with downstream signaling events that influence EMBP expression. The indirect inhibition through SFK modulation showcases the compound's efficacy as a targeted approach to EMBP regulation, providing insights into the specific kinase-dependent regulatory networks governing EMBP dynamics. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly inhibits EMBP expression by disrupting the PI3K/Akt pathway. Inhibition of PI3K by wortmannin leads to reduced Akt activation, influencing downstream targets associated with EMBP regulation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an inhibitor of NF-κB activation, indirectly inhibits EMBP by disrupting the NF-κB signaling pathway. By inhibiting the activation of NF-κB, BAY 11-7082 modulates the transcriptional regulation of genes involved in inflammation, including EMBP. This indirect inhibition highlights the compound's capability to modulate EMBP expression by interfering with a specific regulatory axis associated with inflammatory signaling, offering a targeted approach through NF-κB inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly modulates EMBP expression by targeting the mTOR pathway. Inhibition of mTOR by rapamycin leads to downstream effects on protein synthesis and cellular proliferation, impacting the expression of EMBP. The indirect modulation through mTOR showcases the intricate regulatory networks influencing EMBP, providing a targeted approach to modulation through the specific interference with the mTOR signaling pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly influences EMBP expression by targeting the PI3K/Akt pathway. Inhibition of PI3K leads to reduced Akt activation, affecting downstream targets associated with EMBP regulation. The disruption of PI3K/Akt signaling by LY294002 demonstrates its efficacy as an indirect inhibitor of EMBP, providing mechanistic insight into the regulatory networks governing EMBP dynamics through targeted pathway modulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, indirectly influences EMBP expression by disrupting the JNK signaling pathway. Inhibition of JNK by SP600125 disrupts downstream signaling events, affecting transcription factors involved in EMBP regulation. The impact of SP600125 on the JNK pathway demonstrates its efficacy as an indirect inhibitor of EMBP, offering a specific and targeted approach to modulation through the JNK signaling axis. | ||||||